Technical Analysis for RAIN - Rain Therapeutics Inc.

Grade Last Price % Change Price Change
C 17.55 2.87% 0.49
RAIN closed up 2.87 percent on Wednesday, July 28, 2021, on 21 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical RAIN trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 2.87%
Hammer Candlestick Bullish 2.87%
Stochastic Reached Oversold Weakness 2.87%
Wide Bands Range Expansion 2.87%
Oversold Stochastic Weakness 2.87%
Wide Bands Range Expansion 4.84%
Older End-of-Day Signals for RAIN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 14 hours ago
Up 2% about 14 hours ago
Possible NR7 about 15 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Hammer Candlestick Entry about 19 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancers Prostate Cancer Tumors Antineoplastic Drugs Targeted Therapy Tyrosine Kinase Receptors Bemcentinib

Is RAIN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 23.9
52 Week Low 14.08
Average Volume 176,464
200-Day Moving Average 0.00
50-Day Moving Average 18.26
20-Day Moving Average 18.27
10-Day Moving Average 18.40
Average True Range 1.20
ADX 16.68
+DI 21.12
-DI 30.54
Chandelier Exit (Long, 3 ATRs) 18.61
Chandelier Exit (Short, 3 ATRs) 18.86
Upper Bollinger Bands 21.32
Lower Bollinger Band 15.22
Percent B (%b) 0.38
BandWidth 33.35
MACD Line -0.08
MACD Signal Line 0.18
MACD Histogram -0.2527
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.45
Resistance 3 (R3) 18.35 17.95 18.30
Resistance 2 (R2) 17.95 17.72 18.00 18.25
Resistance 1 (R1) 17.75 17.58 17.85 17.85 18.20
Pivot Point 17.35 17.35 17.40 17.40 17.35
Support 1 (S1) 17.15 17.12 17.25 17.25 16.90
Support 2 (S2) 16.75 16.98 16.80 16.85
Support 3 (S3) 16.55 16.75 16.80
Support 4 (S4) 16.65